Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock

NCT00625209 is registered in ClinicalTrials.gov with University of Versailles as lead sponsor.

NCT NCT00625209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00625209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock
Lead sponsor
University of Versailles
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
July 31, 2016
Enrollment
1,241 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock